CN111643461B - Tablet for treating hypertension and preparation method thereof - Google Patents

Tablet for treating hypertension and preparation method thereof Download PDF

Info

Publication number
CN111643461B
CN111643461B CN201910160855.3A CN201910160855A CN111643461B CN 111643461 B CN111643461 B CN 111643461B CN 201910160855 A CN201910160855 A CN 201910160855A CN 111643461 B CN111643461 B CN 111643461B
Authority
CN
China
Prior art keywords
azilsartan
stirring
melt
tablet
polyethylene glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910160855.3A
Other languages
Chinese (zh)
Other versions
CN111643461A (en
Inventor
张贵民
郝贵周
庞晓娟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lunan Pharmaceutical Group Corp
Original Assignee
Lunan Pharmaceutical Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunan Pharmaceutical Group Corp filed Critical Lunan Pharmaceutical Group Corp
Priority to CN201910160855.3A priority Critical patent/CN111643461B/en
Publication of CN111643461A publication Critical patent/CN111643461A/en
Application granted granted Critical
Publication of CN111643461B publication Critical patent/CN111643461B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention belongs to the technical field of medicinal preparations, and particularly relates to a tablet for treating hypertension and a preparation method thereof. The tablet for treating hypertension comprises a solid dispersion prepared from azilsartan and polyethylene glycol, a filler, a disintegrating agent and a lubricant; the tablet is prepared by the following method: adding azilsartan into polyethylene glycol melt, stirring uniformly, adding into filler and disintegrant, stirring and granulating, adding lubricant into the prepared granules, mixing and tabletting. Compared with the prior art, the invention has the advantages of simple preparation process, better dissolution rate and stable and controllable quality.

Description

Tablet for treating hypertension and preparation method thereof
Technical Field
The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to a tablet for treating hypertension and a preparation method thereof.
Background
Azilsartan is an angiotensin II receptor antagonist drug for treating hypertension, is mostly used for treating hypertension, and is the only angiotensin II receptor antagonist (sartan) drug in the end-stage clinic at present. The medicine is marketed by Wutian pharmaceutical company in Japan in 2012, and the curative effect of the medicine in the clinical stage is obvious.
Azilsartan belongs to a poorly soluble drug, and has a solubility in water of less than 9 mug/ml. The structural formula is as follows:
Figure BDA0001984582500000011
the bioavailability of a drug in the body is greatly affected by the dissolution of the drug. Azilsartan is almost insoluble in water and is a poorly soluble drug, and when the azilsartan is prepared into a pharmaceutical preparation, micronized azilsartan particles are usually adopted, and the particle size is controlled to be below 15 mu m, so that the absorption of the drug in a body and the clinical curative effect of the drug are ensured.
CN101528262A discloses a stable pharmaceutical composition with excellent dissolution property, which contains a low melting point oily and no substance, and a low viscosity adhesive, and is mainly characterized in that the low viscosity adhesive is used to improve the dissolution of azilsartan, but the low viscosity adhesive is used to improve the in vitro dissolution of azilsartan, which is often limited.
CN103705510A discloses a preparation method of an azilsartan solid composition. The preparation method comprises the steps of preparing the azilsartan into a suspension solution, adding the suspension solution into a diluent of the pharmaceutical composition in a spraying mode after wet grinding, and drying to prepare particles and powder of the azilsartan pharmaceutical composition; finally, the granules and the powder are prepared into the azilsartan medicinal minimum dosage unit. Solves the problem that the impurity is increased sharply when the azilsartan particles are prepared by a conventional crushing method, but the process is more complex.
CN102895205A discloses a fast-dissolving azilsartan pharmaceutical preparation, the particle size D90 of azilsartan is less than or equal to 20 mu m, the method improves the dissolution by controlling the particle size, but the dissolution rate still needs to be improved, and the stability of micronized active ingredients is reduced.
CN102793680A discloses an azilsartan solid dispersion, a preparation method and a pharmaceutical composition thereof, wherein the azilsartan and a pharmaceutically acceptable carrier material thereof are adopted to prepare a solid dispersion system, and the dissolution rate of the tablet prepared by the method is still low.
CN106333930A discloses an azilsartan pellet tablet and a preparation method thereof, wherein the azilsartan pellet tablet is prepared by tabletting azilsartan pellets and pharmaceutical excipients, so as to improve the dissolution rate and bioavailability of the drug, but in the preparation process of the fluidized bed pellet tablet, the drug may be loaded on the pellet core in the form of crystal transition, partial crystal transition or amorphous crystal, which affects the exertion of drug effect.
CN104306344A discloses an azilsartan tablet and a preparation method thereof, wherein the azilsartan tablet is prepared by compressing azilsartan, microcrystalline cellulose, KG1000 and other pharmaceutically acceptable auxiliary materials by a dry direct compression process, and the dissolution rate of the prepared tablet needs to be improved.
CN104523632A discloses an azilsartan tablet, which is prepared by dissolving azilsartan and povidone in diethylene glycol ethyl ether, adding silicon dioxide for adsorption, and then mixing with other auxiliary materials and directly pressing. However, the azilsartan tablets directly pressed by powder are difficult to ensure the mixing uniformity although the process is simple, the layering phenomenon is easy to generate in the tabletting process, and the problem of in vitro dissolution is not solved essentially.
CN108553433A, selected from Azilsartan, diluent (I), diluent (II), diluent (III), stabilizer, disintegrant, lubricant and adhesive. The azilsartan tablets prepared by the method have smooth appearance, good hardness, small tablet weight difference and uniform content, but the process is complex, and the in-vitro dissolution needs to be improved.
So far, the problem of poor dissolution rate of azilsartan still cannot be solved by adopting pharmaceutic adjuvants and preparation technologies in the prior art. The prepared azilsartan tablets still have the problems of poor stability, improved safety and the like.
Disclosure of Invention
Aiming at the defects of the prior art, the inventor finds that the drug dispersion degree and the hydrophilicity of the azilsartan can be improved by adopting a solid dispersion melt granulation technology, and further finds that the solid dispersion, a mixture of specific fillers, namely lactose and corn starch, and a disintegrant, namely low-substituted hydroxypropyl cellulose are mixed and pressed into tablets, so that the penetration of water into the tablets can be further accelerated, the disintegration is accelerated, and the dissolution rate and the stability of the azilsartan are improved.
Specifically, the invention is realized by the following technologies:
a solid dispersion for treating hypertension, which comprises a solid dispersion prepared from azilsartan and polyethylene glycol, wherein the weight ratio of the azilsartan to the polyethylene glycol is 1: 1.2-1.8.
The polyethylene glycol specification is selected from one or more of PEG 200-8000.
Preferably, the polyethylene glycol is one or more of PEG 1500-6000.
The solid dispersion for treating hypertension can be further prepared into dosage forms such as tablets, capsules or granules according to textbooks and/or other methods in the prior art, and the original characteristics are still maintained.
The invention further provides a tablet for treating hypertension, which comprises the solid dispersion prepared from the azilsartan and polyethylene glycol, a filler, a disintegrant and a lubricant.
The filler is one or more of lactose, corn starch, microcrystalline cellulose, sucrose, pregelatinized starch, mannitol and sorbitol.
The filler is one or more of lactose, corn starch and microcrystalline cellulose.
Preferably, the filler is a mixture of lactose and corn starch.
Further preferably, the weight ratio of the lactose to the corn starch is 1: 2-3.
More preferably, the weight ratio of lactose to corn starch is 1: 2.5.
The disintegrant is low-substituted hydroxypropyl cellulose.
The lubricant is magnesium stearate.
The tablet for treating hypertension specifically comprises the following components in parts by weight:
Figure BDA0001984582500000031
preferably, the tablet for treating hypertension specifically comprises the following components in parts by weight:
Figure BDA0001984582500000032
the invention also provides a preparation method of the tablet for treating hypertension, which comprises the following steps: adding azilsartan into polyethylene glycol melt, stirring, adding filler and disintegrant into the obtained suspension melt, stirring, granulating, adding lubricant, mixing, and tabletting.
Preferably, the preparation method of the tablet for treating hypertension is prepared by the following steps: adding azilsartan into the polyethylene glycol melt, and uniformly stirring to obtain a suspension melt; weighing the filler and the disintegrant according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the lubricant into the prepared granules, mixing and tabletting.
Compared with the prior art, the invention has the advantages of simple preparation process, rapid tablet disintegration, rapid drug dissolution and better stability.
Detailed Description
The invention is further illustrated by the following examples. It should be properly understood that: the examples of the present invention are given solely for the purpose of illustration and not as limitations of the present invention, and therefore, simple modifications of the present invention in the context of the methods of the present invention are intended to fall within the scope of the claims.
Example 1
1) Prescription
Figure BDA0001984582500000041
2) Preparation method
Adding azilsartan into the melt of polyethylene glycol 4000 and PEG1500, and uniformly stirring to obtain a suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 2
1) Prescription
Figure BDA0001984582500000042
Figure BDA0001984582500000051
2) Preparation method
Adding azilsartan into the polyethylene glycol 2000 molten liquid, and uniformly stirring to obtain a suspension molten liquid;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 3
1) Prescription
Figure BDA0001984582500000052
2) Preparation method
Adding azilsartan into polyethylene glycol 6000 melt, and uniformly stirring to obtain suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 4
1) Prescription
Figure BDA0001984582500000053
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 5
1) Prescription
Figure BDA0001984582500000061
2) Preparation method
Adding azilsartan into the polyethylene glycol 200 melt, and uniformly stirring to obtain a suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 6
1) Prescription
Figure BDA0001984582500000062
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 7
1) Prescription
Figure BDA0001984582500000071
2) Preparation method
Adding azilsartan into polyethylene glycol 10000 molten liquid, and uniformly stirring to obtain suspension molten liquid;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 8
1) Prescription
Figure BDA0001984582500000072
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 9
1) Prescription
Figure BDA0001984582500000073
Figure BDA0001984582500000081
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Example 10
1) Prescription
Figure BDA0001984582500000082
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing microcrystalline cellulose and croscarmellose sodium in the prescribed amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding talcum powder into the prepared granules, mixing, and tabletting.
Example 11
1) Prescription
Figure BDA0001984582500000083
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing lactose and low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 12
1) Prescription
Figure BDA0001984582500000091
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the corn starch and the low-substituted hydroxypropyl cellulose according to the formula amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 13
1) Prescription
Figure BDA0001984582500000092
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the starch and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 14
1) Prescription
Figure BDA0001984582500000093
Figure BDA0001984582500000101
2) Preparation method
Adding azilsartan into polyethylene glycol 10000 molten liquid, and uniformly stirring to obtain suspension molten liquid;
weighing lactose and low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 15
1) Prescription
Figure BDA0001984582500000102
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing mannitol and low-substituted hydroxypropyl cellulose according to the formula amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing and tabletting.
Example 16
1) Prescription
Figure BDA0001984582500000103
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing sorbitol and low-substituted hydroxypropyl cellulose in the formula amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 17
1) Prescription
Figure BDA0001984582500000111
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing sucrose and low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Example 18
1) Prescription
Figure BDA0001984582500000112
2) Preparation method
Adding azilsartan into polyethylene glycol 8000 melt, and stirring uniformly to obtain suspension melt;
weighing the pregelatinized starch and the low-substituted hydroxypropyl cellulose in the formula amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding magnesium stearate into the prepared granules, mixing, and tabletting.
Comparative example 1
1) Prescription
Figure BDA0001984582500000113
Figure BDA0001984582500000121
2) Preparation method
Weighing the azilsartan and povidone PVP-K30 according to the formula amount, adding 400mL of methanol, stirring until the azilsartan and the povidone-PVP-K30 are dissolved, transferring the azilsartan and the povidone-PVP-K30 into a vacuum drying oven, keeping the temperature at 40 ℃, drying under reduced pressure for 24 hours, then crushing, and sieving by a 60-mesh sieve to obtain the azilsartan solid dispersion, wherein the solid dispersion according to the formula amount and auxiliary materials except magnesium stearate are weighed. After uniformly mixing, sieving by a 30-mesh sieve, mixing again, adding the magnesium stearate in the formula amount, uniformly mixing, stamping by using a 9.5mm stamping die, and tabletting the mixture under the weight of 350mg and the pressure of 7-9 kg.
Comparative example 2
1) Prescription
Figure BDA0001984582500000122
2) Preparation method
Adding 400mL of methanol into azilsartan and polyethylene glycol 6000, stirring until the azilsartan and the polyethylene glycol are dissolved, transferring the mixture into a vacuum drying oven, keeping the temperature at 40 ℃, drying under reduced pressure for 24 hours, then crushing, and sieving by a 60-mesh sieve to obtain an azilsartan solid dispersion;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the formula, uniformly mixing with the azilsartan solid dispersion, adding magnesium stearate into the prepared granules, mixing and tabletting.
Comparative example 3
1) Prescription
Figure BDA0001984582500000123
Figure BDA0001984582500000131
2) Preparation method
Adding azilsartan into the povidone melt, and uniformly stirring to obtain a suspension melt;
weighing the corn starch, the lactose and the low-substituted hydroxypropyl cellulose according to the prescription amount, uniformly mixing, adding the suspension melt, stirring and granulating, adding the magnesium stearate into the prepared granules, mixing and tabletting.
Comparative example 4
1) Prescription
Figure BDA0001984582500000132
2) Preparation method
The azilsartan is subjected to jet milling, the milling pressure is 0.4Mpa, D90 is 38 micrometers, the azilsartan is weighed according to the prescription amount, then the azilsartan and pregelatinized starch KG1000 according to the prescription amount are uniformly mixed in a multi-item motion mixer, then the crosslinked povidone, lactose 100 and talcum powder according to the prescription amount are uniformly mixed, and the azilsartan is prepared by pressing the azilsartan and the pregelatinized starch KG1000 according to the prescription amount on a rotary tablet press through a direct tabletting process.
Comparative example 5
1) Prescription
Figure BDA0001984582500000133
2) Preparation method
Azilsartan is micronized, D90 is controlled to be less than 20 micrometers, and the azilsartan is weighed according to the prescription; sieving anhydrous lactose 21AN with 65 mesh sieve, removing granules, and weighing according to the prescription; the micronized azilsartan and the anhydrous lactose are uniformly mixed, the anhydrous lactose 24AN, the magnesium stearate, the sodium carboxymethyl starch, the low-substituted hydroxypropyl cellulose and the silicon dioxide with the prescription amount are added, and the mixture is uniformly mixed and tabletted.
Verification examples
1. Dissolution testing
The azilsartan formulations prepared in examples 1 to 18 of the present invention and comparative examples 1 to 5 were left for a long period of 12 months at 25 ℃ and 60% RH, and the dissolution rates were measured for 0 month and 12 months, respectively.
The examination method is the second method specified in Chinese pharmacopoeia 2010 edition, taking the product, according to the determination method of dissolution rate and release rate (second method of general rule 0931), taking 900ml of phosphate buffer solution with pH of 5.5 as dissolution medium, rotating speed of 50 r/min, operating according to the method, taking 10ml of solution after 5min, filtering, and taking the subsequent filtrate as the test solution. According to the chromatographic conditions under the content measurement item, taking 20 μ L of each of the test solution and the reference solution, respectively injecting into a liquid chromatograph, recording the chromatogram, and calculating the dissolution amount of each tablet.
2. Detection of related substances
The azilsartan formulations prepared in examples 1 to 18 of the present invention and comparative examples 1 to 5 were left for a long period of 12 months at 25 ℃ and 60% RH, and the substances of interest were measured for 0 month and 12 months, respectively.
Taking the product, grinding, taking a proper amount of fine powder (about 10mg of azilsartan), placing the fine powder into a 20ml brown measuring flask, adding methanol to dissolve and dilute the fine powder to a scale, shaking up, filtering, and taking a subsequent filtrate as a test solution; precisely measuring 1ml of the test solution, placing the test solution in a 100ml brown measuring flask, adding methanol to dilute the test solution to a scale, and shaking the test solution uniformly to serve as a control solution. Performing high performance liquid chromatography (appendix V D of the second part of the 2010 edition of Chinese pharmacopoeia). Octadecylsilane chemically bonded silica is used as a filling agent; mobile phase a was pH3.0 buffer (1.36 g potassium dihydrogen phosphate and 1.74g sodium pentane sulfonate were weighed, dissolved by adding 1000ml water, pH adjusted to 3.0 with phosphoric acid), mobile phase B was acetonitrile, linear gradient elution was performed according to the table below, detection wavelength was 251 nm. In addition, an appropriate amount of impurity 1, impurity 2, impurity 3, impurity 4, impurity 5 and azilsartan reference substance are respectively weighed, and methanol is added for dissolving and diluting to prepare a solution containing 0.5mg of azilsartan and 5 micrograms of known impurities per 1ml, and the solution is used as a system test solution; and precisely measuring 10 mu l of system test solution, injecting the system test solution into a liquid chromatograph, recording a chromatogram, and sequentially outputting peaks of the impurity 2, the impurity 1, the azilsartan, the impurity 3, the impurity 5 and the impurity 4, wherein the separation degree among the peaks of the substances meets the requirement. Injecting 10 mul of the contrast solution into a liquid chromatograph, and adjusting the detection sensitivity to ensure that the peak height of the main component chromatographic peak is 10-25% of the full range; then precisely measuring 10 μ L of each of the test solution and the control solution, respectively injecting into a liquid chromatograph, and recording the chromatogram. After deducting the solvent peak, if there is impurity peak in the chromatogram of the sample solution, the peak area of the largest single unknown impurity should not be larger than 0.2 times (0.2%) of the main peak area of the control solution.
Table 1 test results of azilsartan tablets left for 0 month
Figure BDA0001984582500000151
Table 2 test results of azilsartan tablets left for 12 months
Figure BDA0001984582500000152
Figure BDA0001984582500000161

Claims (3)

1. A solid dispersion tablet for treating hypertension is characterized by comprising a solid dispersion prepared from azilsartan and polyethylene glycol, a filler, a disintegrant and a lubricant, wherein the weight ratio of the azilsartan to the polyethylene glycol is 1:1.2-1.8, the filler is a mixture of lactose and corn starch, the weight ratio of the lactose to the corn starch is 1:2-3, the specification of the polyethylene glycol is one or more selected from PEG1500-8000, and the tablet is prepared by the following method: adding azilsartan into polyethylene glycol melt, stirring uniformly, adding the obtained suspension melt into a filler and a disintegrating agent, stirring for granulating, adding a lubricant, mixing and tabletting.
2. The tablet according to claim 1, wherein the disintegrant is low-substituted hydroxypropyl cellulose.
3. The tablet according to claim 1, which comprises the following components in parts by weight:
Figure DEST_PATH_IMAGE002
。
CN201910160855.3A 2019-03-04 2019-03-04 Tablet for treating hypertension and preparation method thereof Active CN111643461B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910160855.3A CN111643461B (en) 2019-03-04 2019-03-04 Tablet for treating hypertension and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910160855.3A CN111643461B (en) 2019-03-04 2019-03-04 Tablet for treating hypertension and preparation method thereof

Publications (2)

Publication Number Publication Date
CN111643461A CN111643461A (en) 2020-09-11
CN111643461B true CN111643461B (en) 2022-09-13

Family

ID=72342469

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910160855.3A Active CN111643461B (en) 2019-03-04 2019-03-04 Tablet for treating hypertension and preparation method thereof

Country Status (1)

Country Link
CN (1) CN111643461B (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793680A (en) * 2011-05-23 2012-11-28 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion and preparation method and medicinal composition thereof
WO2012159511A1 (en) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
CN104546770A (en) * 2015-01-07 2015-04-29 万特制药(海南)有限公司 Azilsartan orally-disintegrating tablet and preparation method thereof
CN104721147A (en) * 2015-04-03 2015-06-24 海南海力制药有限公司 Azilsartan solid dispersion as well as preparation method and medicament composition thereof
CN106309387A (en) * 2015-07-11 2017-01-11 山东新时代药业有限公司 Everolimus tablet

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278909A1 (en) * 2007-06-06 2010-11-04 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
WO2018002673A1 (en) * 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102793680A (en) * 2011-05-23 2012-11-28 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion and preparation method and medicinal composition thereof
WO2012159511A1 (en) * 2011-05-23 2012-11-29 江苏恒瑞医药股份有限公司 Azilsartan solid dispersion, preparation method and pharmaceutical compositions thereof
CN104546770A (en) * 2015-01-07 2015-04-29 万特制药(海南)有限公司 Azilsartan orally-disintegrating tablet and preparation method thereof
CN104721147A (en) * 2015-04-03 2015-06-24 海南海力制药有限公司 Azilsartan solid dispersion as well as preparation method and medicament composition thereof
CN106309387A (en) * 2015-07-11 2017-01-11 山东新时代药业有限公司 Everolimus tablet

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FORMULATION AND DEVELOPMENT OF EXTENDED RELEASE MATRIX PELLETS OF WATER INSOLUBLE AZILSARTAN MEDOXOMIL WITH SOLID DISPERSION;Pande V. V.等;《INDIAN DRUGS》;20190228;第56卷(第2期);第21-30页 *

Also Published As

Publication number Publication date
CN111643461A (en) 2020-09-11

Similar Documents

Publication Publication Date Title
US20220241285A1 (en) Oral capsule and preparation method therefor
CN103933000B (en) Azilsartan tablet and preparation method thereof
CN104306344B (en) A kind of Azilsartan tablet and preparation technology thereof
CN105769782A (en) Empagliflozin tablet, and preparation method and application thereof
CN114288257A (en) Fluvoxamine maleate tablet and preparation method thereof
CN107753455B (en) A tablet containing imidafenacin and its preparation method
CN111067875B (en) Albendazole liquid-solid compressed tablet and preparation method thereof
CN110638768B (en) Preparation method of medicine for treating male erectile dysfunction
CN111643461B (en) Tablet for treating hypertension and preparation method thereof
CN106389428B (en) Composition capable of improving bioavailability and stability of azilsartan and preparation method thereof
CN102988297A (en) Roflumilast solid dispersion and medicinal composition containing same
CN106860408B (en) Glimepiride tablet
CN113876735B (en) Liluzole microsphere preparation and preparation method thereof
CN115969985A (en) Mei' asan potassium tablet and preparation method thereof
CN105030711A (en) Preparation method of Azilsartan tablets
CN106265557A (en) Pharmaceutical composition containing ticagrelor
CN106880597B (en) Everolimus tablet
CN106860407B (en) Rivaroxaban tablet
CN113133978B (en) Azilsartan tablets and preparation method thereof
CN111000812B (en) Preparation method of lacosamide tablets
CN107982228B (en) Dihydroartemisinin tablet and preparation method thereof
CN112691084A (en) Pharmaceutical composition and preparation method thereof
CN113995724B (en) Tablet containing forsythin aglycone solid dispersion
CN113368066B (en) Icariin tablet and preparation method thereof
CN110585159B (en) Tablet containing sirolimus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant